secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001628280-25-015759
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive reports positive pediatric PK results for Anaphylm; NDA submitted to FDA
--------------------------------------------------------------------------------

- Pediatric study (32 patients aged 7-17, >30 kg) shows PK consistent with adult studies; no serious adverse events.
- Anaphylm NDA submitted to FDA; acceptance decision expected in Q2 2025.
- Company targets Q1 2026 launch if FDA approves Anaphylm.
- Positive pediatric data could enable a label covering patients aged 7 and older.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025015759/0001628280-25-015759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025015759/aqst-20250401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-015759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer